{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:04Z","timestamp":1792785844303,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000016","name":"Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Office of the Assistant Secretary for Preparedness and Response"},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The development of novel broad-spectrum antibiotics, with efficacy against both gram-positive and gram-negative bacteria, has the potential to enhance treatment options for acute bacterial skin and skin structure infections (ABSSSIs). Ceftobiprole is an advanced-generation intravenous cephalosporin with broad in vitro activity against gram-positive (including methicillin-resistant Staphylococcus aureus) and gram-negative pathogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>TARGET was a randomized, double-blind, active-controlled, parallel-group, multicenter, phase 3 noninferiority study that compared ceftobiprole with vancomycin plus aztreonam. The Food and Drug Administration-defined primary efficacy endpoint was early clinical response 48\u201372 hours after treatment initiation in the intent-to-treat (ITT) population and the European Medicines Agency-defined primary endpoint was investigator-assessed clinical success at the test-of-cure (TOC) visit. Noninferiority was defined as the lower limit of the 95% CI for the difference in success rates (ceftobiprole minus vancomycin\/aztreonam) &amp;gt;\u221210%. Safety was assessed through adverse event and laboratory data collection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 679 patients were randomized to ceftobiprole (n\u2005=\u2005335) or vancomycin\/aztreonam (n\u2005=\u2005344). Early clinical success rates were 91.3% and 88.1% in the ceftobiprole and vancomycin\/aztreonam groups, respectively, and noninferiority was demonstrated (adjusted difference: 3.3%; 95% CI: \u22121.2, 7.8). Investigator-assessed clinical success at the TOC visit was similar between the 2 groups, and noninferiority was demonstrated for both the ITT (90.1% vs 89.0%) and clinically evaluable (97.9% vs 95.2%) populations. Both treatment groups displayed similar microbiological success and safety profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TARGET demonstrated that ceftobiprole is noninferior to vancomycin\/aztreonam in the treatment of ABSSSIs, in terms of early clinical response and investigator-assessed clinical success at the TOC visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trials Registration<\/jats:title>\n                    <jats:p>NCT03137173.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaa974","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T15:15:36Z","timestamp":1598022936000},"page":"e1507-e1517","source":"Crossref","is-referenced-by-count":62,"title":["Ceftobiprole Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Results of a Phase 3, Randomized, Double-blind Trial (TARGET)"],"prefix":"10.1093","volume":"73","author":[{"given":"J Scott","family":"Overcash","sequence":"first","affiliation":[{"name":"eStudySite Clinical Research, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kim","sequence":"additional","affiliation":[{"name":"Physician Alliance Research Center, Anaheim, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keech","sequence":"additional","affiliation":[{"name":"Saint Joseph\u2019s Clinical Research, Anaheim, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Illia","family":"Gumenchuk","sequence":"additional","affiliation":[{"name":"Vinnytsia M. I. Pyrohov Regional Clinical Hospital, Vinnytsia, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borislav","family":"Ninov","sequence":"additional","affiliation":[{"name":"UMBAL, Pleven, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaneicy","family":"Gonzalez-Rojas","sequence":"additional","affiliation":[{"name":"Optimus U Corp, Coral Gables, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Waters","sequence":"additional","affiliation":[{"name":"eStudySite Clinical Research, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon","family":"Simeonov","sequence":"additional","affiliation":[{"name":"Clinic of Endocrinology, Medical University, Plovdiv, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Saulay","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ionescu","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I","family":"Smart","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E","family":"Jones","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal A","family":"Hamed","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd., Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"2021100523250649600_CIT0001","author":"US Department of Health and Human Services, Food and Drug Administration"},{"key":"2021100523250649600_CIT0002","doi-asserted-by":"crossref","first-page":"e0143276","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"Kaye","year":"2015","journal-title":"PLoS One"},{"key":"2021100523250649600_CIT0003","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021100523250649600_CIT0004","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/21548331.2018.1506673","article-title":"Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States","volume":"46","author":"Keyloun","year":"2018","journal-title":"Hosp Pract (1995)"},{"key":"2021100523250649600_CIT0005","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/ciz004","article-title":"Current treatment options for acute skin and skin-structure infections","volume":"68","author":"Golan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021100523250649600_CIT0006","first-page":"143","article-title":"Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure","volume":"4","author":"Pulido-Cejudo","year":"2017","journal-title":"Ther Adv Infect Dis"},{"key":"2021100523250649600_CIT0007","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00336-08","article-title":"In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections","volume":"52","author":"Amsler","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021100523250649600_CIT0008","author":"Electronic Medicines Compendium."},{"key":"2021100523250649600_CIT0009","author":"European Medicines Agency."},{"key":"2021100523250649600_CIT0010","volume-title":"Performance standards for antimicrobial susceptibility testing: 29th informational supplement: M100Ed29","author":"Clinical and Laboratory Standards Institute.","year":"2019"},{"key":"2021100523250649600_CIT0011","author":"Clinical and Laboratory Standards Institute.","year":"2019"},{"key":"2021100523250649600_CIT0012","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.diagmicrobio.2019.01.015","article-title":"Ceftobiprole activity when tested against contemporary bacteria causing bloodstream infections in the United States (2016\u20132017)","volume":"94","author":"Pfaller","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021100523250649600_CIT0013","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1086\/526527","article-title":"A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections","volume":"46","author":"Noel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021100523250649600_CIT0014","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1128\/AAC.00551-07","article-title":"Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria","volume":"52","author":"Noel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2021100523250649600_CIT0015","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021100523250649600_CIT0016","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-016-0143-3","article-title":"Comparative effectiveness of \u03b2-lactam versus vancomycin empiric therapy in patients with methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia","volume":"15","author":"Wong","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2021100523250649600_CIT0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/cid\/ciu219","article-title":"A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia","volume":"59","author":"Awad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021100523250649600_CIT0018","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"2021100523250649600_CIT0019","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/cid\/ciu296","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa974\/33725373\/ciaa974.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1507\/40511923\/ciaa974.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/73\/7\/e1507\/40511923\/ciaa974.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T00:29:36Z","timestamp":1633739376000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/7\/e1507\/5902794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":19,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,9,8]]},"published-print":{"date-parts":[[2021,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa974","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,9,8]]}}}